MET and hepatocellular carcinoma: Interestingly, this finding mirrors the clinical experience of c-Met inhibitors in HCC,50 where the lack of association between target expression and therapeutic efficacy suggests the need for ongoing research efforts to be addressed at the discovery of biomarkers that can predict benefit from EMT-targeting agents.